Download PDF
Semin Speech Lang 2017; 38(03): 173-183
DOI: 10.1055/s-0037-1602836
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Perspectives on the Psychosocial Management of Oromandibular Dystonia

Allyson D. Page
1   School of Communication Sciences and Disorders, Elborn College, Western University, London, Ontario, Canada
,
Lauren Siegel
1   School of Communication Sciences and Disorders, Elborn College, Western University, London, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Publication Date:
15 June 2017 (online)

   Permissions and Reprints

Abstract

Oromandibular dystonia (OMD) is a rare disorder of movement characterized by tonic muscle contractions that can result in involuntary, repetitive, and patterned muscle contractions of the lingual musculature, labial musculature, and/or muscles of mastication. As a result, dysarthria can be present that can lead to reduced speech intelligibility and have an adverse impact on psychosocial functioning. In this article, we will describe the clinical and speech characteristics of OMD and the various methods of treatment. Then we will introduce and describe patient-reported outcome measures that assess two aspects of psychosocial functioning: communicative participation and quality of life. We will describe the current state of knowledge as it relates to communicative participation and quality of life in this clinical population, and, finally, we will advocate that speech-language pathologists have a unique role in the care of individuals with OMD through the inclusion of patient-reported outcome measures to provide a comprehensive and holistic management plan.

Keywords

Oromandibular dystonia - dysarthria - psychosocial outcomes - communicative participation - quality of life
 

  • References

  • 1 Teemul TA, Patel R, Kanatas A, Carter LM. Management of oromandibular dystonia with botulinum A toxin: a series of cases. Br J Oral Maxillofac Surg 2016; 54 (10) 1080-1084
    CrossrefPubMedGoogle Scholar
  • 2 Gowers WR. A Manual of Diseases of the Nervous System. Vol. 2. 3rd ed. London : Churchill; 1899: 200
    Google Scholar
  • 3 Meige H. Les convulsions de la face, une forme clinique de convulsions facile, bilaterale et mediane. Rev Neurol (Paris) 1910; 20: 437-443
    PubMedGoogle Scholar
  • 4 Tan EK, Jankovic J. Tardive and idiopathic oromandibular dystonia: a clinical comparison. J Neurol Neurosurg Psychiatry 2000; 68 (02) 186-190
    CrossrefPubMedGoogle Scholar
  • 5 Merz RI, Deakin J, Hawthorne MR. Oromandibular dystonia questionnaire (OMDQ-25): a valid and reliable instrument for measuring health-related quality of life. Clin Otolaryngol 2010; 35 (05) 390-396
    CrossrefPubMedGoogle Scholar
  • 6 Tan EK. Oromandibular dystonia. In: Brin MF, Comella CL, Jankovic J. , eds. Dystonia: Etiology, Clinical Features, and Treatment. Philadelphia, PA: Lippincott Williams & Wilkins; 2004: 167-174
    Google Scholar
  • 7 Bakke M, Larsen BM, Dalager T, Moller E. Oromandibular dystonia-functional and clinical characteristics: a report on 21 cases. Oral Surg Oral Med Oral Pathol Oral Radiol 2013; 115 (01) e21-e26
    CrossrefPubMedGoogle Scholar
  • 8 Tarsy D, Simon DK. Dystonia. N Engl J Med 2006; 355 (08) 818-829
    CrossrefPubMedGoogle Scholar
  • 9 Brin MF, Comella CL. Pathophysiology of dystonia. In: Brin MF, Comella CL, Jankovic J. , eds. Dystonia: Etiology, Clinical Features, and Treatment. Philadelphia, PA: Lippincott Williams & Wilkins; 2004: 5-10
    Google Scholar
  • 10 Nutt JG, Muenter MD, Aronson A, Kurland LT, Melton III LJ. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 1988; 3 (03) 188-194
    CrossrefPubMedGoogle Scholar
  • 11 Steinberger D, Topka H, Fischer D, Müller U. GCH1 mutation in a patient with adult-onset oromandibular dystonia. Neurology 1999; 52 (04) 877-879
    CrossrefPubMedGoogle Scholar
  • 12 Dworkin JP. Bite-block therapy for oromandibular dystonia. J Med Speech-Lang Pathol 1996; 4 (01) 47-56
    PubMedGoogle Scholar
  • 13 Møller E, Bakke M, Dalager T. , et al. Somatosensory input and oromandibular dystonia. Clin Neurol Neurosurg 2013; 115 (07) 1141-1143
    CrossrefPubMedGoogle Scholar
  • 14 Lee KH. Oromandibular dystonia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104 (04) 491-496
    CrossrefPubMedGoogle Scholar
  • 15 Papapetropoulos S, Singer C. Eating dysfunction associated with oromandibular dystonia: clinical characteristics and treatment considerations. Head Face Med 2006; 2 (47) 47
    CrossrefPubMedGoogle Scholar
  • 16 Gandhi YR. Oro-mandibular dystonia. Natl J Maxillofac Surg 2010; 1 (02) 150-152
    CrossrefPubMedGoogle Scholar
  • 17 Darley FL, Aronson AE, Brown JR. Differential diagnostic patterns of dysarthria. J Speech Hear Res 1969; a; 12 (02) 246-269
    CrossrefPubMedGoogle Scholar
  • 18 Darley FL, Aronson AE, Brown JR. Clusters of deviant speech dimensions in the dysarthrias. J Speech Hear Res 1969; b; 12 (03) 462-496
    CrossrefPubMedGoogle Scholar
  • 19 Kreisler A, Verpraet AC, Veit S. , et al. Clinical characteristics of voice, speech, and swallowing disorders in oromandibular dystonia. J Speech Lang Hear Res 2016; 59 (05) 940-949
    CrossrefPubMedGoogle Scholar
  • 20 Dykstra AD, Adams S, Jog M. The effect of botulinum toxin type A on speech intelligibility in lingual dystonia. J Med Speech-Lang Pathol 2007; 15 (02) 172-186
    PubMedGoogle Scholar
  • 21 Golper LA, Nutt JG, Rau MT, Coleman RO. Focal cranial dystonia. J Speech Hear Disord 1983; 48 (02) 128-134
    CrossrefPubMedGoogle Scholar
  • 22 Weismer G, Yunusova Y, Bunton K. Measures to evaluate the effects of DBS on speech production. J Neurolinguist 2012; 25 (04) 74-94
    CrossrefPubMedGoogle Scholar
  • 23 Tinter R, Jankovich J. Botulinum toxin type A in the management of oromandibular dystonia and bruxism. In: Brin MF, Hallet M, Jankovich J. , eds. Scientific and Therapeutic Aspects of Botulinum Toxin. Philadelphia, PA: Lippincott Williams & Wilkins; 2002: 1-12
    Google Scholar
  • 24 Karp BI, Goldstein SR, Chen R, Samii A, Bara-Jimenez W, Hallett M. An open trial of clozapine for dystonia. Mov Disord 1999; 14 (04) 652-657
    CrossrefPubMedGoogle Scholar
  • 25 Blanchet PJ, Rompré PH, Lavigne GJ, Lamarche C. Oral dyskinesia: a clinical overview. Int J Prosthodont 2005; 18 (01) 10-19
    PubMedGoogle Scholar
  • 26 Münchau A, Bhatia KP. Uses of botulinum toxin injection in medicine today. BMJ 2000; 320 (7228): 161-165
    CrossrefPubMedGoogle Scholar
  • 27 Blitzer A, Sulica L. Botulinum toxin: basic science and clinical uses in otolaryngology. Laryngoscope 2001; 111 (02) 218-226
    CrossrefPubMedGoogle Scholar
  • 28 Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev 1981; 33 (03) 155-188
    PubMedGoogle Scholar
  • 29 Kazerooni R, Broadhead C. Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystonia. Am J Health Syst Pharm 2015; 72 (04) 301-307
    CrossrefPubMedGoogle Scholar
  • 30 Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 1990; 53 (08) 633-639
    CrossrefPubMedGoogle Scholar
  • 31 Capelle HH, Weigel R, Krauss JK. Bilateral pallidal stimulation for blepharospasm-oromandibular dystonia (Meige syndrome). Neurology 2003; 60 (12) 2017-2018
    CrossrefPubMedGoogle Scholar
  • 32 Foote KD, Sanchez JC, Okun MS. Staged deep brain stimulation for refractory craniofacial dystonia with blepharospasm: case report and physiology. Neurosurgery 2005; 56 (02) E415
    CrossrefPubMedGoogle Scholar
  • 33 Dykstra AD, Domingo Y, Adams SG, Jog M. Examining speech intelligibility and self- ratings of communicative effectiveness in speakers with oromandibular dystonia receiving botulinum toxin therapy. Canadian Journal of Speech Language Pathol Audiol 2015; 39 (04) 334-345
    PubMedGoogle Scholar
  • 34 Page AD, Siegel L, Jog M. Self-rated communication-related quality of life of individuals with oromandibular dystonia receiving botulinum toxin injections. Am J Speech Lang Pathol. 1-8. https://doi.org/10.1044/2017_AJSLP-16-0098
    CrossrefPubMedGoogle Scholar
  • 35 Eadie TL. The ICIDH-2: theoretical and clinical implications for speech-language pathology. J Speech Lang Pathol Audiol 2001; 25: 181-200
    PubMedGoogle Scholar
  • 36 World Health Organization. ICF: International Classification of Functioning, Disability and Health. Geneva: Author; 2001
    PubMed
  • 37 Eadie TL, Yorkston KM, Klasner ER. , et al. Measuring communicative participation: a review of self-report instruments in speech-language pathology. Am J Speech Lang Pathol 2006; 15 (04) 307-320
    CrossrefPubMedGoogle Scholar
  • 38 Hustad KC. Optimizing communicative effectiveness: bringing it together. In: Yorkston K, Beukelman D, Strand EA, Bell KR. , eds. Management of Motor Speech Disorders in Children and Adults. Austin, TX: Pro-Ed; 1999: 483-537
    Google Scholar
  • 39 Yorkston KM, Baylor CR, Dietz J. , et al. Developing a scale of communicative participation: a cognitive interviewing study. Disabil Rehabil 2008; 30 (06) 425-433
    CrossrefPubMedGoogle Scholar
  • 40 World Health Organization. ICIDH: International Classification of Impairments, Disability and Handicap. Geneva: Author; 1980
    PubMed
  • 41 Paul D, Frattali C, Holland A, Thompson C, Caperton C, Slater S. Quality of Communication Life Scale (ASHA QCL). Rockville, MD: ASHA 2004
    PubMedGoogle Scholar
  • 42 Dowling M. From Husserl to van Manen. A review of different phenomenological approaches. Int J Nurs Stud 2007; 44 (01) 131-142
    CrossrefPubMedGoogle Scholar
  • 43 Siegel L. The Consequences of Oromandibular Dystonia on Communicative Participation: A Qualitative Study of the Insider's Experiences [master's thesis]. London: Western University; 2016
    Google Scholar
  • 44 Ma EP, Yiu EM. Voice activity and participation profile: assessing the impact of voice disorders on daily activities. J Speech Lang Hear Res 2001; 44 (03) 511-524
    CrossrefPubMedGoogle Scholar
  • 45 Yorkston K, Beukelman D, Tice R. Speech Intelligibility Test. Lincoln, NE: Institute for Rehabilitation Science and Engineering at Madonna Rehabilitation Hospital; 2011
    Google Scholar
  • 46 Donovan NJ, Velozo CA, Rosenbek JC. The Communicative Effectiveness Survey: investigating its item-level psychometric properties. J Med Speech-Lang Pathol 2007; 15: 433-447
    PubMedGoogle Scholar
  • 47 Yorkston KM, Klasner ER, Swanson KM. Communication in context: a qualitative study of the experiences of individuals with multiple sclerosis. Am J Speech Lang Pathol 2001; 10 (02) 126-137
    CrossrefPubMedGoogle Scholar
  • 48 Charous SJ, Comella CL, Fan W. Jaw-opening dystonia: quality of life after botulinum toxin injections. Ear Nose Throat J 2011; 90 (02) E9-E12
    CrossrefPubMedGoogle Scholar
  • 49 Nastasi L, Mostile G, Nicoletti A, Zappia M, Reggio E, Catania S. Effect of botulinum toxin treatment on quality of life in patients with isolated lingual dystonia and oromandibular dystonia affecting the tongue. J Neurol 2016; 263 (09) 1702-1708
    CrossrefPubMedGoogle Scholar
  • 50 Baylor C, Yorkston K, Eadie T, Kim J, Chung H, Amtmann D. The Communicative Participation Item Bank (CPIB): item bank calibration and development of a disorder-generic short form. J Speech Lang Hear Res 2013; 56 (04) 1190-1208
    CrossrefPubMedGoogle Scholar
  • 51 Hogikyan ND, Sethuraman G. Validation of an instrument to measure voice-related quality of life (V-RQOL). J Voice 1999; 13 (04) 557-569
    CrossrefPubMedGoogle Scholar
  • 52 Jacobson BH, Johnson A, Grywalski C, Silbergliet A, Jacobson G, Benninger MS. Voice Handicap Index (VHI): development and validation. Am J Speech Lang Pathol 1997; 6 (03) 66-69
    PubMedGoogle Scholar
  • 53 Piacentini V, Zuin A, Cattaneo D, Schindler A. Reliability and validity of an instrument to measure quality of life in the dysarthric speaker. Folia Phoniatr Logop 2011; 63 (06) 289-295
    CrossrefPubMedGoogle Scholar